MF6 Stock Overview
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland.
+ 3 more risks
Price History & Performance
|Historical stock prices|
|Current Share Price||€2.03|
|52 Week High||€4.15|
|52 Week Low||€1.74|
|1 Month Change||-22.52%|
|3 Month Change||-15.42%|
|1 Year Change||-49.38%|
|3 Year Change||-57.22%|
|5 Year Change||-74.41%|
|Change since IPO||-96.83%|
Recent News & Updates
|MF6||DE Medical Equipment||DE Market|
Return vs Industry: MF6 underperformed the German Medical Equipment industry which returned 0.2% over the past year.
Return vs Market: MF6 underperformed the German Market which returned -12.2% over the past year.
|MF6 Average Weekly Movement||12.8%|
|Medical Equipment Industry Average Movement||6.5%|
|Market Average Movement||6.4%|
|10% most volatile stocks in DE Market||10.7%|
|10% least volatile stocks in DE Market||3.5%|
Stable Share Price: MF6 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: MF6's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of solid tumors; NanoPlan, a simulation software that helps the treating physicians to define the NanoTherm therapy schedule according to the distribution of the NanoTherm depots in the tumor; and NanoActivator, a magnetic field applicator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce Fundamentals Summary
|MF6 fundamental statistics|
Is MF6 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MF6 income statement (TTM)|
|Cost of Revenue||€808.15k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Jun 30, 2022
|Earnings per share (EPS)||0.49|
|Net Profit Margin||1,147.78%|
How did MF6 perform over the long term?See historical performance and comparison
Is MagForce undervalued compared to its fair value and its price relative to the market?
Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MF6 (€2.03) is trading below our estimate of fair value (€7.84)
Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MF6 is good value based on its PE Ratio (4.1x) compared to the German Medical Equipment industry average (31.2x).
PE vs Market: MF6 is good value based on its PE Ratio (4.1x) compared to the German market (17.3x).
Price to Earnings Growth Ratio
PEG Ratio: MF6 is good value based on its PEG Ratio (0.1x)
Price to Book Ratio
PB vs Industry: MF6 is good value based on its PB Ratio (1.9x) compared to the DE Medical Equipment industry average (2.9x).
How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MF6's forecast earnings growth (50.3% per year) is above the savings rate (-0.05%).
Earnings vs Market: MF6's earnings (50.3% per year) are forecast to grow faster than the German market (7.9% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MF6's revenue (45.8% per year) is forecast to grow faster than the German market (4.9% per year).
High Growth Revenue: MF6's revenue (45.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MF6's Return on Equity is forecast to be low in 3 years time (3.2%).
How has MagForce performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MF6 has a large one-off gain of €24.5M impacting its June 30 2021 financial results.
Growing Profit Margin: MF6 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: MF6 has become profitable over the past 5 years, growing earnings by 45.2% per year.
Accelerating Growth: MF6 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MF6 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16%).
Return on Equity
High ROE: MF6's Return on Equity (47.2%) is considered outstanding.
How is MagForce's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: MF6's short term assets (€2.1M) do not cover its short term liabilities (€11.9M).
Long Term Liabilities: MF6's short term assets (€2.1M) do not cover its long term liabilities (€21.6M).
Debt to Equity History and Analysis
Debt Level: MF6's net debt to equity ratio (84.1%) is considered high.
Reducing Debt: Insufficient data to determine if MF6's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: Insufficient data to determine if MF6's debt is well covered by operating cash flow.
Interest Coverage: Insufficient data to determine if MF6's interest payments on its debt are well covered by EBIT.
What is MagForce current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MF6's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MF6's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MF6's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MF6's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MF6 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ben Lipps (81 yo)
Dr. Benjamin J. Lipps, also known as Ben, serves as Director and Chief Executive Officer at MagForce USA, Inc. He has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG si...
Experienced Management: MF6's management team is seasoned and experienced (9.1 years average tenure).
Experienced Board: MF6's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.
MagForce AG's employee growth, exchange listings and data sources
- Name: MagForce AG
- Ticker: MF6
- Exchange: XTRA
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €59.809m
- Shares outstanding: 29.46m
- Website: https://www.magforce.com
Number of Employees
- MagForce AG
- Max-Planck-Strasse 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.